The following claims are presented for examination:

1. **(currently amended)** A drug delivery device comprising: a drug; and a vascular implant having a blood-contacting surface and a helical formation on the blood contacting surface, the helical formation ~~**having a helix angle between 8º and 20º and**~~ being capable of inducing helical flow ~~**to**~~ **of** blood flowing past the helical formation, and the drug being releasably associated with the helical formation of the vascular implant.

2. **(original)** A drug delivery device according to claim 1 wherein the drug is mixed into the material from which the helical formation is made.

3. **(currently amended)** A drug delivery device according to claim 1 wherein the drug is coated onto the surface of the helical formation. **[[/1]]**

4. **(currently amended)** A drug delivery device according to ~~**any one of the preceding claims**~~ **claim 1** wherein the helical formation is made from a polymer ~~**, preferably a polymer foam, more preferably polyamide, polyester or polyurethane**~~ .

Claims 5-16 **(canceled)**

17. **(new)** A drug delivery device according to claim 4 wherein the polymer is a polymer foam.

18. **(new)** A drug delivery device according to claim 4 wherein the polymer is selected from the group consisting of: polyamide, polyester, and polyurethane.

19. **(new)** A drug delivery device according to claim 4 wherein the drug is bound onto the cellular structure of the polymer.

20. **(new)** A drug delivery device according to claim 1 wherein the drug is selected from the group consisting of: an anticoagulant, an antiplatelet agent, an

angiogenesis inhibitor, a cyclooxygenase inhibitor, a gene therapy agent, and a mixture of two or more of said drugs.

21. **(new)** A drug delivery device according to claim 1 wherein the vascular implant is selected from the group consisting of: an intravascular stent insert, a vascular graft, and a stent graft.

22. **(new)** A drug delivery device according to claim 21 wherein the vascular implant is a stent and the drug delivery device further comprises a sleeve positioned surrounding and/or within the stent.

23. **(new)** A drug delivery device according to claim 22 wherein the sleeve is made from expanded PTFE.

24. **(new)** A drug delivery device according to claim 1 wherein the drug is also releasably associated with the blood-contacting surface of the vascular implant.

25. **(new)** A drug delivery device according to claim 1 wherein at least one further drug is provided releasably associated with the helical formation.

26. **(new)** A drug delivery device according to claim 1 wherein the helix angle of the helical formation is between 8° and 20°.

27. **(new)** A drug delivery device according to claim 1 wherein the helical formation comprises at least one fin.

28. **(new)** A drug delivery device according to claim 27 wherein the at least one fin has the shape of a right-angle triangle in cross-section.

29. **(new)** A drug delivery device according to claim 27 wherein the at least one fin has the shape of an isosceles triangle in cross-section.

30. **(new)** A drug delivery device according to claim 27 where the at least one fin has the shape of a bell in cross-section.

31. **(new)** A drug delivery device according to claim 30 where the at least one fin has the shape of an asymmetric bell in cross-section.

32. **(new)** A drug delivery device according to claim 1 wherein the helical formation comprises a groove.